kabutan

Tsubota Laboratory Incorporated(4890) Summary

4890
TSE Growth
Tsubota Laboratory Incorporated
348
JPY
+5
(+1.46%)
Dec 5, 12:45 pm JST
2.24
USD
Dec 4, 10:45 pm EST
Result
PTS
outside of trading hours
347
Dec 5, 12:43 pm JST
Summary Chart Historical News Financial Result
PER
59.7
PBR
6.95
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
347 JPY 2.23 USD
Previous Close Dec 4
343 JPY 2.20 USD
High Dec 5, 12:44 pm
348 JPY 2.24 USD
Low Dec 5, 9:08 am
342 JPY 2.20 USD
Volume
18,200
Trading Value
6.00M JPY 0.04M USD
VWAP
345.31 JPY 2.22 USD
Minimum Trading Value
34,800 JPY 224 USD
Market Cap
8.98B JPY 0.06B USD
Number of Trades
55
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
133
1-Year High Apr 22, 2025
3,725
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 566,700
Nov 21, 2025 0 717,700
Nov 14, 2025 0 615,600
Nov 7, 2025 0 636,500
Oct 31, 2025 0 644,700
Company Profile
Tsubota Laboratory Incorporated is a biotech venture originating from Keio University. The company focuses on research and development of pharmaceuticals for myopia, dry eye, presbyopia, and brain activation.
Sector
Pharmaceuticals
Tsubota Laboratory Incorporated, a biotech venture born out of Keio University School of Medicine, aims to create groundbreaking innovations in the treatment of myopia, dry eye, presbyopia, and brain-related disorders. The company conducts advanced research in collaboration with affiliated universities and pursues joint development with partner companies to evaluate research outcomes. Its business model is based on generating revenue through joint research and development agreements, licensing agreements, upfront payments, milestone payments, and post-commercialization royalties, which are then reinvested into new research in a cyclical manner. A distinctive feature of the company is its research and development utilizing the high-level expertise of external contracted researchers. Tsubota Laboratory Incorporated adopts a dual strategy, simultaneously developing and marketing pharmaceuticals and medical devices alongside commodity products.